Nuciferine Ameliorates Fatty Acid Accumulation and Iron Death via the PPARα Signalling Pathway, PPARα Inhibitors Block the Protective Effects of Nuc, Resulting in Excessive Accumulation of Iron Ions, Suggesting that Nuc May Be a Potential Drug for the Treatment of NAFLD (Qiu et al., 2024). The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.